Clinical Trial Update: Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial exploring a combination of sintilimab, bevacizumab, and AG chemotherapy as first-line treatment for unresectable advanced or me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• AG chemotherapy
• Bevacizumab (bevacizumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: ORR,OS,PFS | Phase 2 | Status: NOT_YET_RECRUITING